Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

Heart Matters: Integrate CV Risk, Medications & Physical Activity in RA

print
PRINT
insite
SEARCH

Sunday, November 10, 13:00–14:00. Georgia World Congress Center, Atlanta, USA

Moderators: Diane Horowitz, USA; Monica Richey, USA

  1. Cardiovascular Risk Profiles in RA & Physical Activity's Influence on CV Risk Mary Christenson, USA
  2. Common RA Medications: Balancing the Cardiovascular Risks & Benefits Leticia Shea, USA

Back to the ACR/ARP 2019 conference hub

print
PRINT

Related content

12-02-2019 | Cardiovascular disease | Editorial | Article

Cardiovascular risk management in arthritis: Why still a bridge too far?

18-12-2018 | Psoriatic arthritis | Feature | Article

Recognizing and managing cardiovascular risk in PsA patients

02-04-2019 | Rheumatoid arthritis | Highlight | News

Cardiovascular risk associated with conventional, biologic DMARDs characterized

14-01-2019 | Rheumatoid arthritis | Highlight | News

Trial results support management of cardiovascular risk factors in RA patients